FISHAWACK
1.8.2019 15:02:09 CEST | Business Wire | Press release
2e Creative , an internationally recognised healthcare marketing strategy firm focused on launching pharmaceutical and medical device products, has joined the Fishawack Group , after receiving investment from the global healthcare communications group. The 2e deal strengthens Fishawack as one of the largest independent healthcare communications organisations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190801005540/en/
“2e has been on an exhilarating growth trajectory for the past several years,” 2e CEO Ross Toohey said. “We chose Fishawack over a host of other potential investors because their global footprint, expansive capabilities, and entrepreneurial culture represented the greatest advantage for our employees and clients. This is truly the next evolutionary leap for 2e and the brands we serve.”
Fishawack is a global healthcare communications group with offices in London, Oxford, Brighton and Manchester, UK, as well as Philadelphia, New York, and San Diego, USA; 2e adds to the group’s US footprint. The firm’s core strengths in medical communications, strategic consulting, and creative, fits nicely with 2e’s expertise in strategy, creative, digital marketing, sales training, and internal communications. With this breadth of capabilities, Fishawack and 2e can now support clients throughout the entire product development, launch, and growth lifecycle. With the 2e partnership, the Fishawack Group now boasts over 750 employees worldwide, making it among the largest independent healthcare agencies globally.
“Fishawack is one of the new generation of leaders in healthcare communications. We’re challenging the major agency networks by fostering a uniquely collaborative culture across our agency collective,” Fishawack CEO Oliver Dennis said. “We offer the capabilities, scale, and geographical coverage to offer healthcare brands a fresh, new type of partnership value. We’re excited about 2e’s portfolio, capabilities, and brilliant people. Ross has built a great entrepreneurial culture, and we can’t wait to work with the 2e team.”
This partnership is particularly notable for 2e because it comes on the heels of the agency’s appointment to the MM&M Top 100 Healthcare Agencies worldwide, as well as 2e’s three consecutive victories (2015, 2016, 2017) as MM&M “Healthcare Agency of the Year.” Between 2e and sister agencies Dudnyk , Carling Communications , Blue Latitude Health , and Healthcircle , the Fishawack Group is among the most award winning in the field of healthcare marketing.
“We’re very deliberate about the agencies we invest in,” Fishawack Group President Gail Flockhart said. “Clients demand seamlessly blended capabilities, so it’s important that we build collaborative allegiances across the Fishawack Group. It’s best for our clients and our people. 2e brings executive training and organisational optimisation capabilities to the group.”
Advisors to Fishawack included KPMG, Addleshaw Goddard LLP, and financial backers LDC and LGT Capital Partners. 2e’s advisors included Results International, Stoll Keenon Ogden PLLC, and Clifton Larson Allen.
About 2e Creative
Founded in 1999, 2e Creative is a launch and growth agency featuring Fortune 50 clients across pharma, medical device, and research biotech. The agency’s core competencies include branding, marketing strategy, digital marketing, sales training, and meeting/event production. 2e has over 150 employees and operations in Missouri, Indiana, Texas, and California.
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Manchester, Oxford, London, and Brighton), the USA (Philadelphia, PA, New York, NY, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
Fishawack comprises two international divisions, Fishawack Medical Communications , developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative , offering strategic planning, creative development, advertising and promotion, and tactical execution.
We have built our reputation on excellence, creativity, and transparency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom